Kazazian Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kazazian Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$633K	Buy	+4,000	New	+$541K	0.57%	30
2025 Q1	–	Sell	-31,893	Closed	-$2.87M	–	78
2024 Q4	$2.87M	Buy	+31,893	New	+$3.09M	2.2%	12
2016 Q3	–	Sell	-1,253	Closed	-$68K	–	54
2016 Q2	$68K	Sell	1,253 -1,252	-50%	-$68.6K	0.11%	47
2016 Q1	$129K	Buy	+2,505	New	+$130K	0.25%	35

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Kazazian Asset Management's XBI Position: Q2 2026 in Review

Kazazian Asset Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 4,000 shares worth $633K. The stake represents 0.57% of the portfolio and ranks #30 among its holdings. This is a return to the name: Kazazian Asset Management previously reported a position in XBI as recently as Q4 2024.

Kazazian Asset Management first reported a position in XBI in Q1 2016 and has held it in 4 quarters since. The position peaked at $2.87M in Q4 2024. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Kazazian Asset Management held 4,000 shares of State Street SPDR S&P Biotech ETF worth $633K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Kazazian Asset Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.57% of Kazazian Asset Management's portfolio in Q2 2026, its #30 holding.
Kazazian Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 4 quarters since.
Kazazian Asset Management's State Street SPDR S&P Biotech ETF position peaked at $2.87M in Q4 2024.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Kazazian Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.